Clinical Trial Update: Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update reports the tolerance and biologic activity of oral ciclopirox olamine in patients with relapsed or refractory hematologic ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Lymphocytic Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Ciclopirox olamine (Ciclopirox olamine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hematologic Malignancy, Acute Lymphocytic Leukemia | Phase 1 | Status: COMPLETED